A signed purchase order and an approved supplier list can create a comforting illusion: that your phosphatidylserine supply is secured. In reality, a PO binds your supplier to almost nothing beyond the next shipment. It does not reserve production capacity during a shortage, it does not cap prices when raw material costs spike, and it does not obligate the supplier to tell you before they change a carrier system, a solvent process or an upstream concentrate source. When disruption hits a concentrated supply chain — and specialty lipid supply chains do concentrate — the buyers who fare best are those whose relationship rests on a real supply agreement rather than a stack of transactional orders.
Yet many US and EU ingredient buyers negotiate supply agreements rarely enough that the exercise feels unfamiliar, and the resulting contracts often copy generic templates that fit commodity raw materials far better than a concentrated nutraceutical lipid. The clauses that matter for phosphatidylserine are specific: how price adjusts over a multi-year horizon, what volume you actually commit to and what happens if you miss it, how capacity is allocated when demand exceeds supply, and how regulatory continuity is protected when the supplier's process changes.
This guide breaks the agreement into its working parts and identifies, clause by clause, what a technically competent buyer should insist on, what is reasonably negotiable, and what belongs on paper rather than in handshake assumptions.
!alt text For non-GMO and European programmes, our sunflower phosphatidylserine page covers the specification and documentation set buyers typically request.
Why a purchase order is not a supply agreement
Purchase orders specify what you buy this quarter: quantity, grade, packaging, price and delivery terms. What they cannot do is govern the future. A supplier facing two customers with competing demand has no contractual basis to prioritize either one; one hit with a 30 percent rise in upstream concentrate costs can lawfully quote your next PO at a materially higher price; and one who reformulates their powder to run faster on their encapsulation lines can change your flowability profile with nothing more than a revised spec sheet attached to the next shipment.
A supply agreement is the instrument that converts a good commercial relationship into enforceable expectations. It does not need to be long. Some of the most workable ingredient agreements run ten to fifteen pages. What matters is that it addresses the decisions you would otherwise have to renegotiate in the middle of a crisis, when your negotiating position is weakest.
What the agreement should actually cover
Before discussing individual clauses, agree on scope. A workable phosphatidylserine supply agreement should address, at minimum:
- Product definition: grade, derivation (soy or sunflower), assay basis, specification version, packaging format
- Term and renewal: how long it runs and how it is extended or renegotiated
- Pricing: the adjustment mechanism, not just the starting number
- Volume: your commitment, their capacity reservation, and the consequences of missing either
- Quality and change control: change notice, site and process changes, retention samples, audit rights
- Regulatory support: who maintains which declarations as laws change
- Logistics and risk: incoterms, lead times, allocation of constrained supply, force majeure and exit terms
Each of these deserves deliberate negotiation, but three areas cause the most disputes in practice: price, volume and change. The following sections treat each in turn.
Pricing mechanisms: fixed, indexed and review-based
Three pricing structures dominate ingredient supply agreements, and each carries a different balance of risk between buyer and supplier.
A fixed price for the full term is rare for specialty lipids beyond twelve months, and when offered it usually embeds a risk premium. It is attractive for budgeting, but a supplier locked into a fixed price may respond to cost pressure with subtle de-speciation — a cheaper carrier, thinner QC sampling — so pair any fixed price with the audit and change-control rights described below.
An indexed or formula price ties the contract price to an agreed reference — for instance, the supplier's published list price, or a soybean oil or lecithin-related reference for raw material linkage — with a defined adjustment frequency and a cap and collar limiting movement in any period. Formulas work only when the index is genuinely observable by both parties; an index the supplier controls unilaterally turns the formula into a formality.
A periodic review mechanism — typically annual — is the most common middle ground: the price holds for twelve months, then resets through defined negotiation. What makes review clauses workable is structure: require the supplier to substantiate any adjustment with reference data, define a notification window before it takes effect (90 to 180 days is typical), and honor the prior price for volumes committed during the notice period. Whichever mechanism you choose, also fix the price basis explicitly — incoterm, currency and packaging — because an otherwise clear price clause is easily undermined by a vague assumption about delivery terms or exchange rates.
Volume commitments, allocation and priority of supply
Volume clauses cut in both directions. The supplier wants your commitment to justify capacity and pricing; you want flexibility if your sales forecast disappoints. Workable compromises include a base commitment with a tolerance (for example, you commit to take at least 80 percent of forecast volume annually), quarterly rolling forecasts, and a take-or-pay floor only on the portion of price concessions tied to your volume tier.
The clause buyers most often omit — and most desperately need during a shortage — is allocation and priority. Agree in advance that when the supplier's capacity cannot cover all customers, your committed volumes are allocated on a priority basis, and define what evidence of constraint the supplier must provide. Ask directly what percentage of your forecast the supplier can reserve as dedicated capacity, and what notice they require to expand it. A capacity reservation that exists only as a verbal assurance from a sales manager is worth very little in the quarter when demand outruns supply.
Also define surge mechanics: the maximum volume above the committed baseline, on what lead time, and at what price. Specialty lipid lines cannot triple overnight, but most suppliers can flex 20 to 30 percent with adequate notice — if you have asked and written the answer down.
Quality, change control and regulatory continuity clauses
For a buyer of phosphatidylserine, the most commercially consequential quality clause is change notification. Require advance written notice — typically 60 to 90 days before implementation — of any change to manufacturing site, process, raw material source, carrier system or specification that could affect your finished product, with the right to test and approve before the changed material ships. This single clause protects your formulation, your stability data and your regulatory filings far more effectively than any amount of incoming inspection.
Pair it with regulatory continuity obligations: the supplier maintains the declarations your market requires — allergen, GMO, EU novel food status evidence where applicable, TSE/BSE statements, US food facility registration — updates them when regulations change, and responds to documentation requests within a defined time. Specify retention sample obligations and audit rights, including the right to audit after a serious quality event, not only on a routine schedule.
Finally, anchor the agreement to your quality agreement: reference it by version and make compliance a contractual obligation, so commercial and quality duties cannot drift apart.
Force majeure, hardship and exit provisions
Most force majeure clauses are drafted so broadly that they excuse everything and protect no one. Negotiate three specifics. First, definition: force majeure should cover genuinely uncontrollable events, explicitly excluding the supplier's own commercial difficulties and the loss of their upstream supplier's viability — precisely the risk that worries PS buyers most. Second, duties during force majeure: prompt written notice with cause, a duty to mitigate and allocate remaining capacity fairly, and regular status updates. Third, duration consequence: if the event continues beyond a defined period — 90 to 180 days is common — you gain the right to source elsewhere or terminate without penalty.
Exit provisions deserve equal care. Define termination rights for persistent quality failure, repeated late delivery and insolvency, each with a cure period. And plan the transition itself: a wind-down supply obligation that keeps the supplier shipping for a defined period (six to twelve months) after termination, so you can qualify a replacement source without an interruption. The transition clause feels awkward to negotiate while the relationship is healthy; that health is exactly why it must be negotiated then.
Making the agreement work in practice
An agreement only reduces risk if it is lived. Put the annexed specification versions, quality agreement and price schedules under document control, and review them at the annual supplier review you should already be running. Track delivery reliability and COA conformity against the agreement's commitments, and raise gaps in quarterly business reviews while they are small. When a clause is triggered — a change notice, a price adjustment, an allocation event — treat the outcome as precedent and document it. Suppliers and buyers alike calibrate to how the contract behaves in its first real test, so the first test matters disproportionately.
FAQ
Q: How long should a phosphatidylserine supply agreement run?
A: One to three years is the practical range for a specialty lipid. Terms beyond three years are hard to price honestly for either side; a three-year term with an annual pricing review and a renewal mechanism usually balances security and flexibility better than a long fixed deal.
Q: Should the pricing clause be in USD or EUR?
A: Match the currency of your actual payments and state it explicitly, including which party bears exchange-rate movement. If you buy in USD but sell in EUR, an unmanaged currency mismatch inside a multi-year agreement can quietly erase negotiated savings.
Q: Is a supply agreement still worth it if volumes are small?
A: Yes, in simplified form. Even a short agreement fixing price review mechanics, change notification, and priority of supply delivers most of the risk value. Suppliers of specialty ingredients routinely sign two-to-three-page agreements with smaller accounts; complexity should scale with volume, not with legal convention.
Q: What is the single most important clause if I can only negotiate one?
A: Advance change notification with the right to approve affected lots. Nearly every catastrophic PS supply surprise — a failed finished-product validation, an unsupported regulatory claim, a sensory complaint wave — traces back to a change the buyer learned about too late.
Conclusion
A supply agreement is not paperwork for its own sake; it is a pre-negotiated playbook for the moments when the market is not calm. For phosphatidylserine, where production capacity is concentrated and reformulation is slow and expensive, the clauses that matter are precise: an honest pricing mechanism with notice periods, volume commitments paired with genuine capacity reservation and surge mechanics, advance change control anchored to your quality agreement, and a force majeure clause that allocates constrained supply fairly and lets you leave if the interruption outlasts your patience. Negotiate those points while the relationship is strong, keep the annexes under document control, and review performance against the letter of the agreement every year. The best time to build the playbook is the quarter when you do not need it. When you are ready to move from checklist to quotation, contact our team with the grade, source and document set described above.
Sources
- FDA — Contract manufacturing and supplier quality obligations under 21 CFR Part 111 (dietary supplement CGMP): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111
- European Commission — General Food Law Regulation (EC) No 178/2002, operator obligations across the supply chain: https://food.ec.europa.eu/horizontal-topics/general-food-law_en
- ICC — Force Majeure and Hardship Clause guidance 2020: https://iccwbo.org/business-solutions/force-majeure-and-hardship-clause/
- UNIDROIT — UNIDROIT Principles of International Commercial Contracts (hardship and performance context): https://www.unidroit.org/instruments/commercial-contracts/unidroit-principles-2016/
Buyer fit
Who this guide is for
This guide is written for the buyer profiles below. Open your profile for the matching grades, documents and next steps, or tell us your requirements directly.
Recommended next steps
- Review the Phosphatidylserine product page.
- Compare Soy PS and Sunflower PS.
- Check manufacturing proof and Quality & R&D.
Contact sales for product documents
Share source preference, application, country, and annual quantity.
Contact Sales
